NCT06059261 2026-02-18
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Chongqing University Cancer Hospital
Phase 2 Recruiting
Clinical Trials
8 trialsNCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT05112991 2025-05-29
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
3D Medicines
Phase 2 Recruiting
NCT05941325 2025-05-18
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT06791083 2025-01-24
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2 Recruiting
NCT06498622 2024-07-12
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Anhui Provincial Hospital
Phase 2 Recruiting
NCT06014372 2024-04-12
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT06321081 2024-03-20
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Beijing Hospital
Phase 2 Recruiting